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Abstract. 
 
Human aminoacyl–tRNA synthetases (ARSs) 
are normally located in cytoplasm and are involved in 
protein synthesis. In the present work, we found that 
human methionyl–tRNA synthetase (MRS) was trans-
located to nucleolus in proliferative cells, but disap-
peared in quiescent cells. The nucleolar localization of 
MRS was triggered by various growth factors such as 
insulin, PDGF, and EGF. The presence of MRS in nu-
cleoli depended on the integrity of RNA and the activ-
ity of RNA polymerase I in the nucleolus. The riboso-
mal RNA synthesis was speciﬁcally decreased by the 
treatment of anti-MRS antibody as determined by nu-
clear run-on assay and immunostaining with anti-Br an-
tibody after incorporating Br-UTP into nascent RNA. 
Thus, human MRS plays a role in the biogenesis of 
rRNA in nucleoli, while it is catalytically involved in 
protein synthesis in cytoplasm.
Key words: methionyl–tRNA synthetase • nucleoli • 
growth signal • ribosomal RNA synthesis • RNA poly-
merase I
 
Introduction
 
Aminoacyl–tRNA synthetases (ARSs)
 
1
 
 are enzymes de-
coding genetic information into amino acids. Although
these enzymes normally execute their catalytic activities
for protein synthesis, recent reports suggest that they are
not simple enzymes, and they can play novel regulatory
functions in various processes (Martinis et al., 1999).
Mammalian tryptophanyl–tRNA synthetase is induced by
interferon (Kisselev et al., 1993) and the same enzyme of
 
Drosophila melanogaster 
 
is under the control of the ho-
meotic gene, Scr, and highly expressed in salivary gland
during development (Seshaiah and Andrew, 1999). Mito-
chondrial tyrosyl–tRNA synthetase of 
 
Neurospora crassa
 
(Akins and Lambowitz, 1987) and leucyl–tRNA syn-
thetase of 
 
Saccharomyces cerevisiae 
 
(Labouesse, 1990) are
involved in the splicing process. Human tyrosyl–tRNA
synthetase is converted to two distinct proapoptotic cyto-
kines (Wakasugi and Schimmel, 1999) and human arginyl–
tRNA synthetase (RRS) also sequesters the precursor of a
proapoptotic cytokine (Park et al., 1999). Thus, we antici-
pated the unveiling of more diverse functions from these
enzymes.
To gain an insight into the novel functions of mamma-
lian ARSs, we investigated cellular localizations of differ-
ent human ARSs using their specific antibodies. Among
the tested ARSs, methionyl–tRNA synthetase (MRS) was
uniquely localized in the nucleolus. Although the presence
of MRS in nucleoli was previously reported (Dang et al.,
1983), the functional reason for the nucleolar localization
of MRS is not understood. Here, we investigated the
translocational control and functional significance of nu-
cleolar MRS.
Human cytoplasmic MRS consists of 900 amino acids
(Lage and Dietel, 1996) and is one of the components for
the multi-tRNA synthetase complex (Mirande, 1991; Kis-
selev and Wolfson, 1994; Yang, 1996). The core domain is
homologous to the corresponding enzymes from prokaryotes
 
(Fig. 1 A). However, it contains the unique NH
 
2
 
-terminal
extension of 267 amino acids that is not essential for catalytic
activity (data not shown), but is involved in protein–protein
interaction (Rho et al., 1999). Similarly, the NH
 
2
 
-terminal
extension of yeast MRS is also responsible for the interac-
tion with a nuclear pore-associated protein, Arc1p (Simos et
 
al., 1996). Another motif of 
 
z
 
40 amino acids (Fig. 1 A, gray
box) is present in the COOH-terminal region (Q847-K897)
that is homologous to the motifs present in other ARSs and
involved in protein–protein and protein–nucleic acid interac-
tions (Rho et al., 1996, 1998). In addition, putative nuclear
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localization signals (Schimmel and Wang, 1999) are found in
the COOH-terminal region as four consecutive lysines from
K897 to K900 and PWKRIKG from P724 to G730 (Fig. 1 A,
bars), implying that MRS may be translocated to the nu-
cleus. Here, we report that human MRS is translocated into
nucleoli by various cell proliferation signals and is involved
in rRNA synthesis.
 
Materials and Methods
 
Cell Culture
 
HeLa, Chang, HepG-2, COS-1, and human foreskin fibroblast were
grown to subconfluency on 5 
 
3
 
 5-mm glass coverslips in 35-mm petri
dishes in DME supplemented with 10% FBS (GIBCO BRL). Confluent
cells were prepared by growing 5 
 
3
 
 10
 
5
 
 cells on coverslips in DME/10%
FBS for 4–6 d without changing the medium. Quiescent cells were also
prepared by serum starvation for 5–7 d in DME. RNA polymerase I and
RNA polymerase II were inhibited by the addition of cisplatin (10 
 
m
 
g/ml
for 9 h; Jordan and Carmo-Fonseca, 1998) and 
 
a
 
-amanitin (2 
 
m
 
g/ml for
16 h; Kedinger et al., 1970; Lindel et al., 1970), respectively. The inhibition
of RNA polymerase I and II was achieved by the treatment of 
 
a
 
-amanitin
(2 
 
m
 
g/ml for 16 h) and actinomycin D (0.2 
 
m
 
g/ml for 16 h; Perry, 1963).
 
Antibody Preparation
 
The cDNA encoding the full-length human cytoplasmic MRS was isolated
by PCR from pM184 (Rho et al., 1999) as a template using two specific
primers. The PCR product was cleaved with EcoRI and HindIII designed
into each of the primers, and inserted into the same site of pET28a
(Novagen). The resulting plasmid was introduced into 
 
Escherichia coli
 
BL21 (DE3) and induced with IPTG. Since the recombinant MRS was in-
soluble, it was purified as a denatured polypeptide using nickel-affinity
chromatography following the manufacturer’s instruction (Invitrogen).
The native peptide of EPRS (bifunctional glutamyl-prolyl–tRNA syn-
thetase) from D677 to E884, the native NH
 
2
 
-terminal 236 aa of human
QRS (glutaminyl–tRNA synthetase) and the native NH
 
2
 
-terminal 72 aa of
human RRS were also expressed as His-tagged proteins. All of these
polypeptides were also purified using His tag. Each purified polypeptide
was used to raise specific polyclonal rabbit antibodies as described previ-
ously (Park et al., 1999). The IgG from each antiserum was purified by pro-
tein A affinity chromatography according to the manufacturer’s protocol
(BioRad), and the antibody specificity was confirmed by immunoblotting.
 
Confocal Immunofluorescence Microscopy
 
Cellular localizations of different ARSs were investigated using confocal
immunofluorescence microscopy (
 
m
 
 Radiance, BioRad). The cells were
cultured to 
 
z
 
70% confluency on 5 
 
3
 
 5-mm coverslips and then washed
with cold PBS, fixed with 10% formaldehyde for 10 min at room tempera-
ture, washed with PBS, and then incubated in PBS containing 100 mM
NH
 
4
 
Cl for 10 min at room temperature. After washing the fixed cells with
PBS, the cells were permeabilized with 0.1% Triton-X 100 in PBS for 5
min at room temperature, washed with PBS, and blocked with 0.5% BSA
in PBS for 1 h. The cells were then incubated with polyclonal rabbit anti-
bodies raised against different ARSs in PBS containing 0.5% BSA for 2 h
at 37
 
8
 
C. After washing the primary antibody, the FITC-conjugated sec-
ondary antibody was added and ARSs were detected using a confocal la-
ser scanning microscope. Nucleolin was stained, as described above, using
antinucleolin primary (Santa Cruz) and rhodamine-conjugated secondary
antibodies.
 
Immunoblotting
 
The nuclear extract and postnuclear supernatant were prepared from the
Figure 1. Structural arrange-
ment of human MRS and
specificity of anti-ARS anti-
bodies. A, MRSs of M. pneu-
moniae, S. cerevisiae, and H.
sapiens are aligned schemati-
cally. The core catalytic do-
main is divided into the
NH2- and COOH-terminal
domains (marked with amino
acid numbers and dotted
lines). The signature se-
quences for class I ARSs
(HIGH and KMSKS; Web-
ster et al., 1984; Hountondji
et al., 1986; Ludmerer and
Schimmel, 1987) are high-
lighted by bars. Human MRS
contains the NH2- and
COOH-terminal extensions
that are involved in protein–
protein interactions (Rho et
al., 1999). An z40 aa peptide
motif (marked as gray box)
homologous to those in other
ARSs is present in the
COOH-terminal end (Rho et
al., 1996, 1998). Two nuclear
localization signals (NLS) are
present in the COOH-termi-
nal region. B, Polyclonal rab-
bit antibodies were raised
against the purified polypep-
tides of human MRS, EPRS, RRS, and QRS (see Materials and Methods). The antigenic specificities of the prepared antibodies were
determined by immunoblotting of proteins extracted from HeLa cells. 
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cultured HeLa cells as described previously (Neufeld and White, 1997).
MRS, YY1, lamin B, and heat shock protein 90 (Hsp90) were reacted with
their corresponding antibodies (anti-YY1 and -lamin B antibodies from
Santa Cruz; anti-Hsp90 antibody from Transduction Laboratories) and
detected using the ECL system (Amersham Pharmacia Biotech).
 
Gel Filtration of ARSs
 
The subconfluent HeLa cells (three 150-mm dishes) were lysed in 1 ml of
25 mM Hepes, pH 7.4, 150 mM NaCl, 10% glycerol, and 0.5% Triton
X-100. After the lysate was centrifuged at 25,000 
 
g
 
 for 30 min, the super-
natant was filtered through a 0.22-
 
m
 
m membrane filter and concentrated
using viva spin (VIVASCIENCE) to the protein concentration of 20 mg/
ml. The concentrated protein extract was then loaded into Superdex 200
HR (exclusion limit of 1,300 kD) using AKTA-FPLC (Amersham Phar-
macia Biotech) and eluted at the flow rate of 0.25 ml/min. The eluted pro-
teins in each fraction were analyzed by immunoblotting with anti-MRS,
anti-p43 (Park et al., 1999), and anti-EPRS rabbit antibodies.
 
Nuclear Run-on Assay
 
Synthesis of rRNA was monitored by nuclear run-on assay as described
previously (Giraudo et al., 1998). The nuclei isolated from HeLa cells were
mixed with the indicated amounts of rabbit IgG or anti-MRS antibody at
room temperature for 10 min. Transcription was carried out by addition of
the nuclei to the reaction mixture in the presence of 
 
a
 
[
 
32
 
P] UTP (3,000 Ci/
mmol, New England Nuclear). The synthesized radioactive 18S and 28S
rRNAs were quantified by hybridization to their respective cDNAs that
were immobilized on Hybond membrane (Amersham Pharmacia Biotech.)
using Bio-Dot apparatus (BioRad). The amount of the hybridized radioac-
tive transcripts were quantified by phosphor image analyzer (FLA 3000,
Fuji). The cDNA encoding 
 
b
 
-actin was used as an internal control.
 
Immunostaining of Nascent rRNA with
Anti-BrdU Antibody
 
To monitor the rRNA synthesis, Br-UTP was incorporated into nascent
rRNA and detected by confocal immunofluorescence microscopy using an
antibody specific to Br (Sigma Chemical Co.). HeLa cells cultured on cov-
erglass were briefly washed twice with a PBS buffer (pH 7.4), and with
permeabilization buffer (20 mM Tris-HCl, pH 7.4, 5 mM MgCl
 
2
 
, 0.5 mM
EGTA, 0.5 mM PMSF). The cells were then permeabilized with the same
buffer containing 0.05% Triton X-100 for 5 min at room temperature and
washed with the permeabilization buffer without Triton X-100. The per-
meabilized cells were used for nuclear run-on assay. The synthesis of
rRNA was initiated by adding 50 mM Tris-HCl, pH 7.4, 100 mM KCl, 5
mM MgCl
 
2
 
, 0.5 mM EGTA, 25 U/ml RNasin, 1 mM PMSF, 0.5 mM of
ATP, CTP, and GTP, and 0.2 mM Br-UTP (Sigma Chemical Co.) in the
presence of different antibodies (5 
 
m
 
g/ml each of anti-MRS, anti-QRS,
and mock rabbit IgG), or in the presence of 
 
a
 
-amanitin (1 
 
m
 
g/ml) or cis-
platin (10 
 
m
 
g/ml). The reactions were continued for 30 min at 37
 
8
 
C. The
cells were then washed with a PBS buffer containing 25 U/ml RNasin at
room temperature. The cells were then fixed with PBS containing 10%
fresh formaldehyde, 25 U/ml RNasin, and 0.1% BSA for 20 min at room
temperature and washed twice with 0.1% BSA in PBS for 5 min. The cells
were then treated with PBS containing 0.1% Triton X-100 and 0.1% BSA
for 10 min at room temperature and washed twice with PBS containing
0.1% BSA for 5 min. An anti-Br antibody (1:100) was then reacted in PBS
containing 0.5% BSA and 2% CAS for 2 h at 37
 
8
 
C, and washed three
times with PBS containing 0.1% BSA for 5 min. Then, the FITC-conju-
gated secondary antibody was reacted in PBS containing 0.5% BSA and
2% CAS for 1 h at 37
 
8
 
C. After washing the cells, the incorporated Br-UTP
was monitored by confocal immunofluorescence microscopy. The nuclei
were stained with propidium iodide (10 
 
m
 
g/ml) as described previously
(Andreassen et al., 1998).
Figure  2. Nucleolar localization
of MRS. A, Distributions of four
different ARSs in Chang cells
were determined by immu-
nostaining using confocal laser
scanning microscopy. B, top, Cel-
lular localization of MRS was
monitored in different cell lines.
Human foreskin fibroblast,
HeLa, HpG2, and COS-1 cells
were cultivated and stained with
anti-MRS as described above.
Bar, 10 mm. Bottom, Localiza-
tion of MRS and nucleolin in
Chang cells was determined us-
ing anti-MRS rabbit antibody
and mouse monoclonal anti-
nucleolin antibody (Santa Cruz)
as described in Materials and
Methods. 
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Results
 
Nucleolar Localization of MRS
 
To investigate cellular distribution of different ARSs, poly-
clonal antibodies that were specific to MRS, EPRS, RRS,
and QRS were prepared. Their antigenic specificity was de-
termined by immunoblotting of the proteins extracted
from HeLa cells. All of the antibodies showed specificity to
their antigens (Fig. 1 B). Using these antibodies, cellular
distribution of four different ARSs was investigated by im-
munostaining. Although all of these enzymes were de-
tected in both the nucleus as well as the cytoplasm, relative
partitions between the two cellular locations and staining
patterns were idiosyncratic (Fig. 2 A). Among them, MRS
was uniquely stained at nucleoli, implying its novel func-
tion at this site. Removal of anti-MRS IgG from anti-MRS
antiserum decreased nucleolar and cytoplasmic staining
and mock rabbit IgG or preimmune serum did not give any
specific MRS signal (data not shown).
The nucleolar localization of MRS was further investi-
gated in the different cells by confocal immunofluorescence
microscopy using an anti-MRS antibody. The nucleolar
MRS was detected in all of the human foreskin fibroblast,
HeLa, HepG2, and COS-1 cells, indicating that the nucle-
olar localization of MRS is universal in mammalian cells
(Fig. 2 B). The nucleolar localization of MRS was confirmed
by coimmunostaining of MRS with nucleolin that was used
as a marker for nucleoli. MRS was exactly colocalized with
nucleolin, confirming its nucleolar localization (Fig. 2 B).
The presence of MRS at nucleoli was then investigated by
immunoblotting of nuclear and postnuclear fractions of
HeLa cells. The transcription factor, YY1 (Shi et al., 1991),
and nuclear structural protein, lamin B (Moir et al., 1995),
and HSP90 (Koyasu et al., 1986) were used as nuclear and
cytoplasmic markers, respectively. The marker proteins
were found in the expected fractions, indicating that the nu-
clei were well isolated. MRS was found both in nucleus as
well as in postnuclear supernatant (Fig. 3, top). Since MRS
is a component of the multi-ARS complex, the presence of
MRS in nucleus implies that at least some portion of MRS
should exist as a different form. This possibility was investi-
gated by size exclusion chromatography (exclusion limit of
1,300 kD) of the proteins extracted from the HeLa cells.
The multi-ARS complex would be eluted in the void vol-
ume from this column because its approximate molecular
weight is 1,500 kD. The proteins eluted from the column
were resolved by gel electrophoresis. MRS and two other
complex-components, EPRS (Fett and Knippers, 1991) and
p43 (Quevillon et al., 1997), were detected by immunoblot-
ting with their respective antibodies. The majority of the
three proteins were coeluted in the void volume as ex-
pected. However, a significant amount of MRS was also de-
tected in the following fractions in which EPRS and p43
were barely detected (Fig. 3, bottom). This result implies
that MRS may be loosely associated with the multi-ARS
complex or that a portion of MRS may exist unassociated
from the multi-ARS complex.
 
MRS Is Translocated to Nucleoli by Cell
Proliferation Signal
 
We then investigated the condition in which MRS is trans-
located to nucleolus. The cultured Chang cells were fixed
at two different growth stages (subconfluent and conflu-
ent) and stained with an anti-MRS antibody. The nucle-
olar MRS was only detected in subconfluent cells, suggest-
ing that the nucleolar localization of MRS is dependent on
cell growth conditions (Fig. 4, top, left and middle). The
nucleolar MRS disappeared by serum starvation (Fig. 4,
top, right), but was restored by the addition of 10% serum,
or mitogenic signals such as EGF, PDGF, and insulin (Fig.
4, bottom). Thus, the nucleolar localization of MRS is trig-
gered by a cell growth signal, but is not specific as to the
type of signal.
 
Nucleolar MRS Requires rRNA and
Polymerase I Activity
 
Cell proliferation would accelerate many biological pro-
cesses, including ribosome biogenesis (Grummt, 1999).
Since the nucleolus is the site for rRNA synthesis, the nu-
cleolar MRS that is induced by the cellular proliferation
signal may be related to rRNA synthesis. To gain insight
into the function of the nucleolar MRS, we first tested
whether or not its nucleolar localization requires RNA in
the nucleolus. HeLa cells were treated with DNase I or
RNase A after fixation, and the cellular location of MRS
was monitored by immunostaining. The nucleolar MRS
disappeared with the treatment of RNase, but not DNase
(Fig. 5, top). This result suggests that the nucleolar local-
ization of MRS requires RNA in nucleolus.
We then investigated whether or not the presence of
MRS is dependent on the activity of RNA polymerase I
that is responsible for rRNA synthesis. The nucleolar
MRS disappeared with the addition of 
 
a
 
-amanitin and ac-
tinomycin D (Perry, 1963) or cisplatin (Jordan and Carmo-
Figure  3. Determination of nuclear and free form MRS. Top,
MRS was detected by immunoblotting in the whole cell lysate
(WCL), nuclear extract (NCL), and postnuclear supernatant
(PNS). Cell fractionation was performed as described previously
(Neufeld and White, 1997). YY1, lamin B, and Hsp90 were used
as nuclear and cytoplasmic markers, respectively. Bottom, The
proteins extracted from HeLa cells were fractionated by size ex-
clusion chromatography. The eluted proteins in each fraction
were analyzed by immunoblotting with anti-MRS, -p43 (Park et
al., 1999), and -EPRS rabbit antibodies. 
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Fonseca, 1998) that inhibited RNA polymerase I. How-
ever, it was not affected by the treatment of the RNA
polymerase II inhibitor, 
 
a
 
-amanitin (Kedinger et al., 1970;
Lindel et al., 1970; Fig. 5, bottom). These results suggest
that the nucleolar MRS is related to rRNA synthesis.
 
Anti-MRS Antibody Blocks rRNA Synthesis
 
The effect of MRS on rRNA synthesis was then investi-
gated by a nuclear run-on assay and immunostaining of
 
nascent rRNA. The HeLa cell nuclei were isolated and the
transcription was carried out in the presence of different
amounts of anti-MRS antibody. The synthesized RNAs
were isolated and hybridized with 18S and 28S rDNAs, as
well as cDNA for 
 
b
 
-actin that was used for internal con-
trol. The synthesis of two rRNAs was decreased by the ad-
dition of anti-MRS antibody, in a dose-dependent manner,
to 20% of the control in which no antibody was added
(Fig. 6). In contrast, mock rabbit IgG did not affect the
synthesis of 18S and 28S rRNAs and the amounts of
Figure 4. MRS is translocated
to nucleolus upon a mitogenic
signal. Top, Cellular localiza-
tion of MRS was monitored in
Chang cells as described in
Fig. 2. The nucleolar MRS
was apparent in subconfluent
(z70% confluency) cells, but
disappeared in confluent
(100% confluency) or 5-d se-
rum-starved cells. Bottom,
10% serum or EGF (40 ng/
ml), PDGF (40 ng/ml), and
insulin (100 mg/ml) were
added to 7-d serum-starved
cells and the cells were ob-
served 24 h after the treat-
ment. Bar, 10 mm.
Figure 5. Nucleolar localiza-
tion of MRS depends on
rRNA synthesis. Top, HeLa
cells grown on glass cover-
slips were permeabilized in
0.1% Triton X-100 for 5 min
at room temperature. The
permeabilized cells were in-
cubated with DNase I (0.1
mg/ml) or RNase A (0.1 mg/
ml) for 1 h at 378C and fixed
in 10% formaldehyde for 20
min. Digestion of nuclear
DNA was confirmed by
DAPI staining (data not
shown). Bottom, HeLa cells
were treated with a-amanitin
(2 mg/ml), and a-amanitin (2
mg/ml) 1 actinomycin D (0.2
mg/ml), for 16 h to inhibit
RNA polymerase II and
RNA polymerase I 1 II, re-
spectively. The specific inhi-
bition of RNA polymerase I
was performed by incubat-
ing HeLa cells with cisplatin
(10 mg/ml) for 9 h. The cellu-
lar localization of MRS was
monitored by immunostain-
ing as described above. Bar,
10 mm. 
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b
 
-actin RNA were unchanged by the treatment of anti-
MRS antibody. These results indicate that anti-MRS anti-
body specifically affected the synthesis of rRNA.
We also monitored the rRNA and mRNA synthesis by
the immunostaining of Br-UTP incorporated to the na-
scent RNA. Ribosomal RNA synthesis, executed by RNA
polymerase I, was shown as nucleolar foci, whereas syn-
thesis of mRNA by RNA polymerase II was detected as
nucleoplasmic foci. The nucleolar foci disappeared with
the treatment of an anti-MRS antibody, but not by mock
rabbit IgG (Fig. 7 A). The nucleoplasmic foci remained
unaffected by either of the two antibodies. We then re-
peated these similar experiments focusing on the nucleolar
rRNA synthesis in a few different conditions. Nuclei were
stained using propidium iodide. Again, an anti-MRS anti-
body specifically inhibited rRNA synthesis, whereas mock
rabbit IgG and anti-QRS antibody did not. The nucleolar
Br-staining of rRNA was also confirmed by its sensitivity
to the treatment of cisplatin, but not of 
 
a
 
-amanitin (Fig. 7
B). All of these results clearly suggest that MRS is in-
volved in the synthesis of rRNA.
 
Discussion
 
Several mammalian ARSs form a macromolecular protein
complex (Mirande, 1991; Kisselev and Wolfson, 1994; Yang,
1996). However, the presence of free forms has been re-
ported in a few different ARSs that are the components for
the complex (Mirande et al., 1983; Vellekamp et al., 1983,
1985). Here, the four complex-forming ARSs showed differ-
ent patterns in immunostaining (Fig. 2 A). These results im-
ply that at least some portions of the complex-forming ARSs
are distributed differently in a cell, while most of them are
present within the macromolecular protein complex.
Human MRS is also a component of this multi-ARS
complex. However, MRS dissociated from the multi-ARS
complex may exist based on the elution profile from size
exclusion chromatography and its presence in the nucleus
(Fig. 3). MRS in nuclear fraction was also eluted from the
gel filtration column as a macromolecular complex (data
not shown), implying that it is also associated with other
nuclear factors or structure. This observation is consistent
with its localization in nucleoli. Human MRS contains
peptide extensions attached to the NH
 
2
 
- and COOH-ter-
minal ends of the core catalytic domain (Fig. 1 A). Inter-
estingly, these two peptide appendices are involved in
protein–protein interactions (Rho et al., 1999) and phos-
phorylation sites for casein kinase II are heavily clustered
in the NH
 
2
 
-terminal appendix (data not shown). Since
casein kinase II is involved in the growth control and regu-
lation of rRNA synthesis (Voit et al., 1995; Hannan et al.,
1998), phosphorylation of MRS at these sites may be re-
lated to the nucleolar localization of MRS. However, we
failed to determine the peptide region responsible for the
nucleolar localization of MRS, because various forms of
recombinant MRS were not well expressed and gave a cy-
totoxic effect in transfected cells (data not shown).
The nucleolus is the nuclear site in which rRNA biogen-
esis takes place. Interestingly, it was reported previously
that nucleoli show an independent protein synthesis capa-
bility (Lamkin et al., 1973) and contain some components
of protein synthesis, such as the elongation factor (Rao et
al., 1998). Electron microscopic analysis also suggested the
presence of a few ARSs in nucleoli (Popenko et al., 1994).
However, the condition and physiological meaning for the
presence of these factors in nucleolus has not been under-
stood. Here, we report that the cytoplasmic MRS is trans-
located into nucleolus by various cellular proliferation sig-
nals (Fig. 4) and is involved in rRNA synthesis (Figs. 6 and
7). Interestingly, 5S rRNA is associated with MRS and en-
hances its activity in cytoplasm (Ogata et al., 1991). MRS
may be also bound to 5S rRNA in nucleolus and regulate
the biogenesis of ribosome.
The ribosome biogenesis of prokaryotes is subjected to
stringent control mediated by unusual nucleotides in re-
sponse to uncharged tRNA (Cozzone, 1980). Amino acid
starvation drops the nucleolar rRNA synthesis as well as
the cytoplasmic protein synthesis in eukaryotic cells. This
suggests the presence of a mechanism sensing the cellular
level of the amino acid. Although eukaryotes do not seem
to employ unusual nucleotide messengers analogous to
those of prokaryotes for this communication (Pollard et
al., 1980), many protein factors have recently been found
in nucleolus and are involved in rRNA synthesis. For in-
Figure 6. Nuclear run-on assay for rRNA synthesis. Ribosomal
RNA synthesis is blocked with anti-MRS antibody. Top, Synthe-
sis of rRNA was monitored by nuclear run-on assay as described
previously (Giraudo et al., 1998). The nuclei isolated from HeLa
cells were used for the assay. The synthesized transcripts were
hybridized to 18S and 28S rDNAs or cDNA for b-actin on the
membrane. The amounts of the hybridized transcripts were
quantified by phosphor image analyzer. Bottom, The radioactive
intensities of 18S, 28S, and b-actin blots without IgG were taken
as 100% and the relative intensities of other blots were shown by
percentage. White bars stand for the values of the intensities of
18S and 28S treated with the indicated amounts of mock rabbit
IgG. Black, gray, and lined bars represent the relative intensities
of the 18S, 28S, and b-actin blots treated with the indicated
amounts of anti-MRS antibody, respectively. Similar results were
obtained from three independent experiments. 
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stance, a zinc finger protein, ZPR1, is associated with the
cytoplasmic domain of EGF receptor in quiescent cells
(Galcheva-Gargova et al., 1996), but translocated to nucle-
olus to activate rRNA synthesis by a cell proliferation sig-
nal (Galcheva-Gargova et al., 1998). In reverse, a tumor
suppressor, retinoblastoma protein, is translocated to nu-
cleolus to inhibit rRNA synthesis during cellular differen-
tiation (Cavanaugh et al., 1995). In this sense, MRS is an
ideal molecule, coordinating rRNA synthesis in the nucle-
olus and protein synthesis in cytoplasm.
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